QuantumCat specializes in advanced indoor air quality solutions powered by our innovative catalyst technology. Our proprietary catalysts are uniquely engineered to actively target and eliminate harmful gases and odors, including carbon monoxide (CO), volatile organic compounds (VOCs), sulfur, and ammonia—all at room temperature.
QuantumEye
QuantumEye is an AI technology company developing camera-based intelligent parking and safety solutions. Using multi-CCTV vision, re-identification, and license plate restoration, it enables precise indoor vehicle guidance, risk detection, and smart mobility services. Its platform supports scalable deployment and future integration with a
Quantum HiTech Co., Ltd.
Quantum Hi-Tech delivers innovative battery management solutions built on the full lifecycle of EV batteries. Through real-time safety monitoring & precision diagnostics, our platform ensures batteries remain in optimal condition. By leveraging advanced data modeling & AI-powered services, we are paving the way toward a sustainable future
Qsimplus
QSIMPLUS delivers integrated Quantum communication solutions that combine both advanced software and hardware. We provide practical, plug-and-play systems optimized for secure and scalable deployment. QSIMPLUS accelerates the adoption of real-world Quantum networks and the path toward the future Quantum Internet.
PUTTIATTI
Puttiatti is a specialized manufacturer and brand operator of infant products, managing two distinct brands: PUTTIATTI and BEBEPICK. With in-house facilities including silicone injection molding machines, blow molding machines, and specialized printing lines, the company directly produces silicone bottles, nipples, PPSU bottles, and straw cups. A standout in their lineup is the PUTTIATTI LePure Silicone Baby Bottle, launched in 2026. This groundbreaking product marks the dawn of the “True Full Silicone Bottle” era by replacing the traditional plastic locking mechanisms found in conventional silicone bottles with an innovative silicone structure. The LePure Silicone Baby Bottle is currently undergoing the global patent application process. In addition to this flagship innovation, the company continues to develop and manufacture a wide range of premium products, including various silicone straw cups and high-quality PPSU baby bottles and straw cups.
PurpleAI
PurpleAI is a fast-growing medical AI pioneer transforming stroke care through intelligent automation—enhancing workflow efficiency and diagnostic accuracy to drive better patient outcomes. Building on the proven success of its diagnostic support AI solutions, PurpleAI is now expanding into multi-modal, predictive analytics. Its upcoming flagship SaMD, StrokeShieldAI, is designed to anticipate and monitor high-risk complications following initial stroke treatment. By equipping clinicians with real-time foresight, StrokeShieldAI enables earlier intervention, mitigates adverse outcomes, and sets a new standard for stroke care. | Founded as an independent company in October 2024 (after operating within SK Group since 2019), PurpleAI is a fast-growing medical AI innovator transforming stroke care through intelligent automation and predictive insight—enhancing workflow efficiency, diagnostic accuracy, and patient outcomes. PurpleAI is expanding its Hyper Insight™ portfolio across multiple imaging modalities and advancing into multi-modal, data-driven predictive analytics. Its upcoming flagship, StrokeShieldAI, is built to anticipate and monitor high-risk complications after initial stroke treatment—providing clinicians with real-time foresight for earlier intervention and better outcomes.
PROTEINA
PROTEINA has developed the first-in-class “Single-Molecule Co-Immunoprecipitation”-based general platform, which enables precise measurement of protein-protein interactions (PPIs) at the single-molecular level. At PROTEINA, we’ve spent over a decade delving into the intricacies of protein-protein interactions. The wealth of knowledge and experience we’ve gained is reflected in our diverse range of research services and products that we offer to our clients and research partners. These offerings include biomarker discovery for drug development, deciphering the mechanisms of pharmaceutical compounds, and identifying the ideal drug dose of a specific drug treatment. Ultimately, we see our goal of developing accurate, reliable companion diagnostic devices slowly become a reality. The outstanding efforts of the individuals who make up PROTEINA have been gaining recognition through the numerous collaborations and service contracts with well-established pharmaceutical and biotechnology organizations over the years. Our journey began in a small university laboratory over a decade ago, but we have grown to possess the capacity to create cutting-edge technology that is highly valued in the current market. Today, we continue to strive to establish ourselves as a strong competitive force in the global environment. My ultimate goal for PROTEINA is to make meaningful contributions to society by facilitating scientific breakthroughs and innovations. To achieve this, we are committed to attracting and retaining top talent who share our mission. We also strive to maintain a corporate culture that encourages open communication and collaboration among all team members, ensuring that we arrive at the best solutions collectively. With the help of our talented pool of professionals, we aim to further enhance PROTEINA’s technology. By doing so, our products and services will play a critical role in advancing the development of new drugs to combat a wide range of serious illnesses. This, in turn, will be the driving force behind our growth from a company into a global organization. | PROTEINA is a precision therapeutics company translating protein interaction biology into next-generation drugs. Our proprietary SPID platform generates quantitative PPI data at a scale and resolution unavailable with conventional methods — fueling our commercial services, internal pipeline, and AbGPT-3D. Lead programs include PRT-101, a preclinical DMOAD for osteoarthritis, and PRT-1309, a GIPR antagonist antibody targeting obesity and metabolic disease. Our platform anchors a ₩47B national consortium with Samsung Bioepis. We are looking for licensing and co-development partners.